CVRx gets $84m cash injection for Rheos
This article was originally published in Clinica
Executive Summary
CVRx is looking to wrap up clinical studies of its Rheos hypertension control device after securing $84m in its fifth and latest round of financing. New Enterprise Associates and Johnson & Johnson Development Corp were the co-lead investors. The Minneapolis, Minnesota firm will also use the funds to complete product development and build a sales infrastructure in anticipation of a product launch. In addition, the company plans to begin clinical research in the use of Rheos for treating heart failure. The implantable device will be marketed as an alternative treatment option for patients who cannot have their hypertension controlled by drugs. Rheos works by activating the carotid baroreceptors, which play a key role in the body's natural cardiovascular regulation system.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.